Bronchogen: Handling, Storage, and Reconstitution Guide

This Bronchogen handling and storage guide covers lab best practice for Bronchogen (AEDL, Ala-Glu-Asp-Leu), a lyophilized research peptide. Lyophilized means freeze-dried into a powder. The guide covers reconstitution for in vitro prep, cold-chain storage, aliquoting, and record keeping. Every step below is framed as lab procedure, not human-use instruction.

How should Bronchogen be stored?

Store sealed, lyophilized Bronchogen at or below 25 degrees Celsius, away from heat, light, and moisture. It ships as a solid, white powder in a sealed glass vial. Its molecular weight is about 446.45 g/mol. For long-term storage, keep the vial lyophilized and refrigerated or frozen. This helps protect the material.

These conditions match the usual practice across the Khavinson short peptides and the wider cognitive and nootropic range. Teams that handle neurotrophic batches at the same time can compare cold-chain notes with the Cerebrolysin handling guide. That guide follows similar rules for a very different, mixture-based material.

Bronchogen is supplied as a 20 mg vial. It is a single, defined tetrapeptide, not a mixture. So storage aims to protect one tested molecule. That makes both the stability question and the supporting records simpler.

How is Bronchogen reconstituted for in vitro prep?

For in vitro work, Bronchogen is usually reconstituted with bacteriostatic water. Add the water slowly down the side of the vial. Let the powder dissolve without hard mixing. Swirl gently rather than shake, since this helps protect the tetrapeptide.

The exact working concentration depends on the assay. It should follow the study design, not any fixed formula.

Do reconstitution under clean conditions. Use calibrated pipettes and proper PPE, in line with lab SOPs. This is standard reagent prep for in vitro use, not a route of administration.

Pick a diluent that suits the later assay. Record the exact concentration made. This keeps the working stock traceable to the batch it came from. Labs can match concentration to the model by reviewing the Bronchogen research applications.

How should Bronchogen be aliquoted to limit freeze-thaw?

Split the solution into single-use aliquots, or small portions. This limits repeated freeze-thaw cycles, which can break down peptides over time. Product papers note that reconstituted peptide should be kept cold. It should be used within the time frame set by the lab protocol.

Good aliquoting practice usually includes:

• Splitting reconstituted material into single-use volumes to avoid repeated freeze-thaw.
• Labeling each aliquot with compound name, concentration, lot number, and date.
• Logging storage location so the cold chain stays easy to audit.

These rules are shared across the category. The same cold-chain logic appears in the DSIP handling guide.

How stable is Bronchogen once in solution?

Bronchogen is fairly stable as a sealed, cool, dry powder, but less so once mixed. After reconstitution it becomes a working solution with a shorter useful window. Product papers note that reconstituted peptide should be kept cold. It should be used within the time frame set by the lab protocol.

So the study design must set a validity period. It should not assume the solution lasts forever. A practical approach has three parts:

• Reconstitute only what a set of tests needs.
• Keep the rest of the material lyophilized.
• Treat any solution kept past the protocol window as expired.

Log temperature swings, even ones that seem minor. A steady cold chain is part of what lets labs trace results to the peptide and not to breakdown.

Material may move between storage, a biosafety cabinet, and a bench. Keep that transit brief. Return stock quickly to its rated temperature. This protects both the lyophilized reserve and any aliquoted working solution.

What does the Bronchogen Certificate of Analysis confirm?

Each Bronchogen batch ships with a third-party-verified Certificate of Analysis, or CoA. It provides research-grade quality control. The CoA includes:

• A purity check by HPLC or reverse-phase chromatography.
• Identity confirmation by mass spectrometry.
• Lot number, test date, and method details.

For a fixed tetrapeptide, a mass-spectrometry check means a lot. A measured mass that matches the expected value near 446.45 g/mol supports the identity of the AEDL sequence. Purity by chromatography then shows how much of the material is the intended peptide. The rest is process-related impurities. This purity figure matters most for repeatable results.

Recording the lot number next to test results ties data back to one batch. This supports repeatable results across runs. Sample CoAs can be requested as PDFs before purchase. They let labs confirm test settings, methods, and batch consistency.

Material and records are on the Bronchogen product page. Steady handling and CoA checks are what make the readouts in the Bronchogen mechanism of action repeatable.

What safety and compliance steps apply to Bronchogen?

Handle Bronchogen as a research chemical. Only trained staff should work with it, in controlled spaces. Use engineering controls where required. Dispose of it in line with lab and local rules.

Follow lab SOPs, chemical hygiene plans, and approved protocols. Wear proper PPE, including a lab coat, gloves, and eye protection.

Keep storage conditions steady and records complete for the whole study. This supports both quality control and audit readiness. Outside checks are encouraged, since the peptide's evidence base is regional and has been repeated by few groups abroad. Labs often recheck identity and purity in house before using a batch in a long study.

What does a Bronchogen handling checklist include?

A short handling checklist keeps the record complete from receipt to disposal:

• On receipt, check the vial, quantity, and lot against the Certificate of Analysis, and log its condition on arrival.
• Store the sealed lyophilized vial at or below 25 degrees Celsius, or refrigerated to frozen for long holding.
• Reconstitute only the volume a set of tests needs, and record the diluent and concentration used.
• Aliquot, label, and log each working stock, then retire any solution held past the protocol window.
• Keep the CoA and batch records with test data so results stay traceable to one lot.

Much of the Bronchogen literature is regional and preclinical. This level of record keeping lets other labs read reported gene-regulation findings in a shared frame. It also helps them try to repeat those findings.

For research use only. Bronchogen is a research peptide and is not approved for human or veterinary use. All handling guidance refers to laboratory procedure only.